Glenmark cuts prices of its COVID-19 drug FabiFlu to USD 1 per pill
Category: #health  | By Nikita Chaurasia  | Date: 2020-07-15 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Glenmark cuts prices of its COVID-19 drug FabiFlu to USD 1 per pill

As per credible sources, Mumbai-based Glenmark Pharmaceuticals Ltd. recently revealed that it has slashed the price of its coronavirus drug FabiFlu by 27%, from USD 1.37 to USD 1 per pill.

The company is reportedly passing on the profits it accumulated from a better scale and higher yield since both formulations and API (active pharmaceutical ingredients) are developed in Glenmark’s facilities in India. API is developed at Glenmark’s production facility in Gujarat and the formulation is produced in the firm’s facility in Himachal Pradesh.

Glenmark mentioned in a comment that it has started a post-marketing survey of FabiFlu in around 1,000 patients to closely monitor the safety and efficiency of the drug. The company added that these patients are prescribed with the oral antiviral as a part of a multi-center, open label and single-arm study.

According to industry experts, DCGI (Drug Controller General of India) had recently approved the production of Glenmark’s branded generic of favipiravir, following the successful trials in May. The recent development follows the initiation of similar trials of the drug by Cipla Ltd., which is a rival to Glenmark.

However, the drug approval has faced significant criticism from medical fraternity since it is meant for patients suffering from mild COVID-19, which can be cured at home with current treatments including paracetamol, claim sources with the knowledge of the matter.

Glenmark Senior Vice President and Head of India Business Alok Malik was reported saying that the company had introduced FabiFlu in the India at the lowest cost as compared to other countries. He added that this additional price reduction of the drug will provide better accessibility to the patients.

For those uninitiated, the price of FabiFlu in Russia is at USD 7.97 per pill, while in Japan, the drug is worth USD 4.65 per tablet. Additionally, FabiFlu’s price in China and Bangladesh is at USD 2.86 and USD 4.65 per pill respectively. 

In the other news, Glenmark is reportedly conducting trials regarding the combined use of umifenovir and favipiravir for treating patients who are hospitalized with moderate COVID-19 symptoms.

Source Credits –

https://www.livemint.com/companies/news/glenmark-slashes-covid-19-drug-fabiflu-price-by-27-to-75-a-pill-11594688709266.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Goldman Sachs provides unlimited holidays to its senior employees

Goldman Sachs provides unlimited holidays to its senior employees

By Nikita Chaurasia

Goldman Sachs has recently announced a flexible vacation scheme under which the company’s senior employees can take unlimited paid leaves annually. As per sources, the global investment bank has unveiled a new policy that will allow senior sta...

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...